ConductScience.org, home

Paper35596242

Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Fehily SR and 11 others. Aliment Pharmacol Ther, 2022. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Papers, record 35596242. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35596242

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
PubMed
Journal
Aliment Pharmacol Ther
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
5.08
iCite
Revised in PubMed
2024-09-01
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fehily SRSasha Rhttps://orcid.org/0000-0001-5344-2548
2Al-Ani AHAysha Hhttps://orcid.org/0000-0002-4735-5234
3Abdelmalak JJonathanhttps://orcid.org/0000-0001-7550-8202
4Rentch CClarissa
5Zhang EEva
6Denholm JTJustin T
7Johnson DDouglas
8Ng SCSiew Chttps://orcid.org/0000-0002-6850-4454
9Sharma VVishalhttps://orcid.org/0000-0003-2472-3409
10Rubin DTDavid Thttps://orcid.org/0000-0001-5647-1723
11Gibson PRPeter R
12Christensen BBritthttps://orcid.org/0000-0002-8746-4275

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Inflammatory Bowel DiseasesMajor topic
Latent TuberculosisMajor topic
Humans
Immunosuppression Therapy
Interferon-gamma Release Tests
Mass Screening
Tuberculin Test
Tumor Necrosis Factor-alpha

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36641788Letter: Ozanimod and latent tuberculosis.https://conductscience.org/library/papers/36641788

Source PubMed

Download CSV of comments and corrections

References163

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110764341
Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.
Am J Respir Crit Care Med2000https://conductscience.org/library/papers/10764341PubMed
217021358An official ATS statement: hepatotoxicity of antituberculosis therapy.Am J Respir Crit Care Med2006https://conductscience.org/library/papers/17021358PubMed
332387584Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis.Joint Bone Spine2020https://conductscience.org/library/papers/32387584PubMed
415610671Health Risks Associated with Visiting Friends and Relatives in Developing Countries.Curr Infect Dis Rep2005https://conductscience.org/library/papers/15610671PubMed
527484275British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Br J Dermatol2016https://conductscience.org/library/papers/27484275PubMed
629757355A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.J Crohns Colitis2018https://conductscience.org/library/papers/29757355PubMed
725130049Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses.Br J Dermatol2014https://conductscience.org/library/papers/25130049PubMed
827192092Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27192092PubMed
922062358Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.Gastroenterology2012https://conductscience.org/library/papers/22062358PubMed
1020393175Infliximab, azathioprine, or combination therapy for Crohn's disease.N Engl J Med2010https://conductscience.org/library/papers/20393175PubMed
1110228190Infliximab for the treatment of fistulas in patients with Crohn's disease.N Engl J Med1999https://conductscience.org/library/papers/10228190PubMed
1224454900Tuberculosis contact investigation using interferon-gamma release assay with chest x-ray and computed tomography.PLoS One2014https://conductscience.org/library/papers/24454900PubMed
1327683798Long-term Efficacy of Vedolizumab for Crohn's Disease.J Crohns Colitis2017https://conductscience.org/library/papers/27683798PubMed
1422803615The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.Br J Dermatol2012https://conductscience.org/library/papers/22803615PubMed
1516678077Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.Clin Gastroenterol Hepatol2006https://conductscience.org/library/papers/16678077PubMed
1627780211The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.PLoS Med2016https://conductscience.org/library/papers/27780211PubMed
1721180608Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?Ther Adv Gastroenterol2010https://conductscience.org/library/papers/21180608PubMed
1831656117High risk of activation of latent tuberculosis infection in rheumatic disease patients.Infect Dis (Lond)2020https://conductscience.org/library/papers/31656117PubMed
1918564448
Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors--March 2008 update.
Rev Port Pneumol2008https://conductscience.org/library/papers/18564448PubMed
2030373275Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015.J Clin Med2018https://conductscience.org/library/papers/30373275PubMed

See all 163 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42704580IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review.Dig Dis Sci2026https://conductscience.org/library/papers/42704580PubMed
42351542Detection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy.Diagnostics (Basel)2026https://conductscience.org/library/papers/42351542PubMed
42291945Biologic Therapy in Ulcerative Colitis: A Retrospective Real-World Study in a Brazilian Tertiary University Hospital.Cureus2026https://conductscience.org/library/papers/42291945PubMed
42125169Coexisting Hepatic and Renal Dysfunction During Pulmonary Tuberculosis Treatment: A Case Report.Clin Case Rep2026https://conductscience.org/library/papers/42125169PubMed
42039264Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: A 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects.Acta Pharm Sin B2026https://conductscience.org/library/papers/42039264PubMed
41803488Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.J Gastroenterol2026https://conductscience.org/library/papers/41803488PubMed
41446278CD14- CD16+ monocyte PD-L1 prevents early tuberculosis progression and constrains reactivation under immune checkpoint therapy.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41446278PubMed
41399929Dormant yet dangerous: the role of cell rest in perseverance.Future Microbiol2025https://conductscience.org/library/papers/41399929PubMed
40980788A Fatal Case of Anti-PL-7 Antibody-Associated Rapidly Progressive Interstitial Lung Disease Complicated by Tuberculosis: A Case Report.Cureus2025https://conductscience.org/library/papers/40980788PubMed
40764876Assessing tuberculosis risk in Crohn's disease patients receiving biologic therapies: real-world insights from Japan.Intest Res2025https://conductscience.org/library/papers/40764876PubMed
40725683Prevalence and Risk Factors of Latent Tuberculosis Infection Detected by IGRA in Patients with Immune-Mediated Inflammatory Diseases Before and During Biologic DMARD Therapy (TITAN Study).J Clin Med2025https://conductscience.org/library/papers/40725683PubMed
40580415Role of fecal calprotectin to differentiate between treatment-naive intestinal tuberculosis and Crohn's disease: A pilot study.Indian J Gastroenterol2026https://conductscience.org/library/papers/40580415PubMed
40430808Reactivation of Latent Tuberculosis Following COVID-19 and Epstein-Barr Virus Coinfection: A Case Report.Pathogens2025https://conductscience.org/library/papers/40430808PubMed
40421289Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China.Front Med (Lausanne)2025https://conductscience.org/library/papers/40421289PubMed
40236937Persistent Abdominal Pain and Diarrhea After Appendectomy-Crohn's Disease Versus Intestinal Tuberculosis.JGH Open2025https://conductscience.org/library/papers/40236937PubMed
40197143Age-specific relationship between HIV and TB treatment outcomes in the West Region of Cameroon: a cross-sectional study.BMC Infect Dis2025https://conductscience.org/library/papers/40197143PubMed
40059900Biologics in the management of pediatric inflammatory bowel disease: When and what to choose.World J Clin Pediatr2025https://conductscience.org/library/papers/40059900PubMed
40046059Association of systemic inflammation response index with latent tuberculosis infection and all-cause mortality: a cohort study from NHANES 2011-2012.Front Immunol2025https://conductscience.org/library/papers/40046059PubMed
39987456Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn's disease.J Crohns Colitis2025https://conductscience.org/library/papers/39987456PubMed
39257584HBHA induces IL-10 from CD4+ T cells in patients with active tuberculosis but IFN-γ and IL-17 from individuals with Mycobacterium tuberculosis infection.Front Immunol2024https://conductscience.org/library/papers/39257584PubMed

See all 32 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35596242

GET https://conductscience.org/api/papers/v1/35596242/references?page=2